Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

In a 31-center phase 2 trial in 10 countries, apecotrep BI 764198 reduced proteinuria in patients with primary focal segmental glomerulosclerosis.  


Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial

Andrew Vissing shares his clinical perspective and strategies to mitigate gaps in care and management for young adults with glomerular disease.


Implementing Age-Specific Care For Young Adults With Glomerular Disease With Andrew Vissing, MD

New CureGN findings and an interview with Andrew Vissing, MD, highlight distinct glomerular disease outcomes in adolescents and young adults compared with pediatric and adult patients


Unmet Needs of Glomerular Disease in Young Adults, Adolescents With Andrew Vissing, MD

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

HCPLive 5 Stories in Under 5: Week of 01/11

The FDA has extended its review of the sNDA, delaying the previous January 13, 2026, PDUFA date, to April 13, 2026.



FDA Extends Sparsentan (Filspari) sNDA Review for Focal Segmental Glomerulosclerosis

An age-based observational study in glomerular disease suggests different rates of disease progression and remission in young adults compared to adult and pediatric patients. 


Adolescents, Young Adults With Glomerular Disease May Require Distinct Care

A review of 32 years of global data on FSGS highlights increased prevalence, with a limitation of biopsy variation and regional practices.


Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis

A curated recap of 8 impactful trial updates from the American Society of Nephrology Kidney Week 2025.

Kidney Week 2025 Recap: 8 Trial Updates to Know in Nephrology

Sparsentan shows superior proteinuria reduction in pediatric FSGS patients, setting the stage for potential FDA approval.

Understanding Sparsentan in Pediatric FSGS, With Michelle Rheault, MD

New findings reveal sparsentan significantly reduces proteinuria in FSGS patients, offering hope for improved kidney health and lower failure risk.

DUPLEX: Sparsentan Outperforms Irbesartan in Reaching Key Proteinuria Threshold in FSGS

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 